| ID | 1005 |
| Name of the vaccine | Infanrix |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 6 years |
| Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed (DTaP vaccine). |
| Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
| Name of the manufacturing country | Belgium and Germany |
| Year of manufacture | 1997 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | Levels of diphtheria antitoxin greater than or equal to 0.01 IU/mL were achieved in 100% of the sera tested. |
| Vaccine formulation | Suspension for injection |
| Dosage | 0.5 ml injection with 5 dose series. One dose at 2,4 and 6 months. One booster dose at 15-20 months and another at 4-6 years. |
| Mechanism of action | Serum diphtheria antitoxin level of 0.1 IU/ml is protective. |
| Route of administration | Intramuscular |
| Indications | Prevents against diphtheria, tetanus and acellular pertussis. |
| Export | Distributed by - GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | Also for tetanus and pertussis. |
| Side effects of vaccine | Pain, redness, swelling, fever, drowsiness, irritability and loss of appetite. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/75157/download |
| Other name | NA |
| Additional Links | NA
|